Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions

Abstract

Purpose To provide whole-body physiologically based pharmacokinetic (PBPK) models of the potent clinical organic anion transporter (OAT) inhibitor probenecid and the clinical OAT victim drug furosemide for their application in transporter-based drug-drug interaction (DDI) modeling. Methods PBPK models of probenecid and furosemide were developed in PK-Sim®. Drug-dependent parameters and plasma concentration-time profiles following intravenous and oral probenecid and furosemide administration were gathered from literature and used for model development. For model evaluation, plasma concentration-time profiles, areas under the plasma concentration–time curve (AUC) and peak plasma concentrations (Cmax) were predicted and compared to observed data. In addition, the models were applied to predict the outcome of clinical DDI studies. Results The developed models accurately describe the reported plasma concentrations of 27 clinical probenecid studies and of 42 studies using furosemide. Furthermore, application of these models to predict the probenecid-furosemide and probenecid-rifampicin DDIs demonstrates their good performance, with 6/7 of the predicted DDI AUC ratios and 4/5 of the predicted DDI Cmax ratios within 1.25-fold of the observed values, and all predicted DDI AUC and Cmax ratios within 2.0-fold. Conclusions Whole-body PBPK models of probenecid and furosemide were built and evaluated, providing useful tools to support the investigation of transporter mediated DDIs.

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals

“…As the potent clinical organic anion transporter (OAT) inhibitor, probenecid could inhibit OAT3 activity, while NPT1 is not affected. The probenecid model applied was developed by Britz et al (2020) . After the PBPK models were developed, we validated the developed PBPK model by comparing the simulated plasma concentration-time curves with the corresponding clinical studies.…”

Prediction for optimal dosage of pazopanib under various clinical situations using physiologically based pharmacokinetic modeling

“…Next, MATE2-K concentration in human kidney organ was calculated by formula (transporter expression × 26.2 mg/g × kidney weight) from the literature ( Scotcher et al, 2017 ). The final inputting parameters used in PBPK model for PAZ are listed in Table 2 ( Drozdzik et al, 2019 ; Li et al, 2019 ; Britz et al, 2020 ; Reddy et al, 2021 ; Krens et al, 2022 ; PMDA, 2022 ). The generic workflow of the PBPK model is represented in Figure 1 .…”

Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures

“…This is already evident for biomarkers like CPI, NMN, and PDA and no doubt that future efforts will encompass others like TAU, GCDCA-S, and IBC. 5,[78][79][80][81][82][83][84][85] Further progress will require the refinement of PBPK model compound files for each biomarker, which will necessitate the acquisition of basic information (e.g., BPR, renal FR, synthesis rate, turnover, and ft). In this regard, it is important to understand that SLC biomarker PKs and response to perpetrator drugs may be impacted by disease, organ impairment, (epi)genetics, gender, pregnancy, age, smoking, food intake, exercise, diurnal effects, and any myriad of other factors that might modulate their formation and clearance.…”